Lichtenfeld #NGDx18 The world is changing; the disruptors are changing the cost structure. 'Lower cost somewhere else.'
5:13pm August 20th 2018 via Twitter Web Client
Pratt #NGDx18 Other NGS testing was reimb so low she shut it down and sends it out instead.
5:10pm August 20th 2018 via Twitter Web Client
Pratt #NGDx18 Comments on PAMA: OMB seeing better savings ($780M). And most CMS reimb rates have gone up. New tests… https://t.co/JtmbqMF4R6
5:09pm August 20th 2018 via Twitter Web Client
Lichtenfeld #NGDx18 We have a long way to go... QALY valued at $36K in the UK? Here is $50K-$100K for QALY. Will it improve outcomes?
5:07pm August 20th 2018 via Twitter Web Client
Lichtenfeld #NGDx18 But part of the battle: when do you find signal in cfDNA, and what really makes a difference in the outcome?
5:06pm August 20th 2018 via Twitter Web Client
Lichtenfeld #NGDx18 We will need to understand what works, what doesn't. cfDNA: is now moving into early-det phase.
Dietzen #NGDx18 Value is not (always) single-test, single-outcome. Life-saving many times.
5:00pm August 20th 2018 via Twitter Web Client
Leite #NGDx18 CDx may be viewed as a restriction of the market; for Loxo, viewed as an expansion, for multi-gene testing.
4:58pm August 20th 2018 via Twitter Web Client
Leite #NGDx18 Clinicians in China has physicians much more value-based in their thinking (may be due to self-payer situation)
4:56pm August 20th 2018 via Twitter Web Client
Q: how do you see value based from industry? Leite #NGDx18 A primary concern; pricing is tied back to reimbursible… https://t.co/r47aE0QBBe
4:54pm August 20th 2018 via Twitter Web Client
Van Meter #NGDx18 Now is moving toward value for public health issues (antibiotic resistance for example)
4:52pm August 20th 2018 via Twitter Web Client
Van Meter #NGDx18: @AdvaMedDx developed a model of value-based metrics, to both Pts and physicians, also value of speed of test
4:51pm August 20th 2018 via Twitter Web Client
Van Meter: @AdvaMedDx developed a model of value-based metrics, to both the pt and physician; also speed of the test
4:50pm August 20th 2018 via Twitter Web Client
Add'l panelists for #NGDx18 include: Victoria Pratt (Indiana U, AMP President-Elect), Susan Van Meter (AdvaMedDx);… https://t.co/lnaKulK4FX
4:40pm August 20th 2018 via Twitter Web Client
Cecilia Schott (AstraZeneca) moderator for #NGDx18 panel; Dennis Dietzen (WashU); John Leite (Illumina); Leonard Lichtenfeld (ACS);
4:39pm August 20th 2018 via Twitter Web Client
Dietzen #NGDx18 Reimb. has historically been cost-based; but what is the value? Accountible care?
4:36pm August 20th 2018 via Twitter Web Client
Dietzen #NGDx18 Increasing test volume, cost; PAMA/novel coding; demand for clin utility evidence; value-based care
4:34pm August 20th 2018 via Twitter Web Client
Dietzen #NGDx18 Payers seek to better control Dx test costs but often fail to realize what they need is 'better ove… https://t.co/p2biJtPCV2
4:33pm August 20th 2018 via Twitter Web Client
Dietzen #NGDx18 "Theranos was literally a black box; make it any color except for black, please!"
4:30pm August 20th 2018 via Twitter Web Client
Dietzen #NGDx18 Opportunities: LDT vs IVD, new FDA pathwasy, EQA. Challenges - lack of transparency, 'Bad Actors', EU IVD directives
Dietzen #NGDx18 Different Dx modes into each aspect of the central dogma; with breadth and depth. Innovation across… https://t.co/MMMWbWJyiN
4:28pm August 20th 2018 via Twitter Web Client
Plenary panel at #NGDx18 Policy and prediction for diagnostics. Dennis Dietzen (President of AACC, WashU)
4:27pm August 20th 2018 via Twitter Web Client
Jia #NGDx18 Plans to go beyond blood to urine. Other two tests: ATLAS, (600 gene panel for TMB), Hereditary, 25-gene incl BRCA.
3:31pm August 20th 2018 via Twitter Web Client
Jia #NGDx18 Shows CNA data from cfDNA of AR gene.
3:28pm August 20th 2018 via Twitter Web Client
Jia #NGDx18 Difference in var calls between RNA and DNA: AR AF starts at zero, goes up post-Rx.
3:22pm August 20th 2018 via Twitter Web Client
Jia #NGDx18 Shows AR-V7 MOA in metastatic colorectal prostate cancer over course of Rx, relapse by PSA level
3:21pm August 20th 2018 via Twitter Web Client
Jia #NGDx18 Able to pick up ctDNA based detection of MET exon skipping; also AR-V7 splicing variants.
3:20pm August 20th 2018 via Twitter Web Client
Jia #NGDx18 RNA splicing, fusions; DNA shows PPV 93.0%. Shows RNA + DNA increasing sens down to 0.06% AF.
3:18pm August 20th 2018 via Twitter Web Client
Jia #NGDx18 Guardant and FMI doing 'outstanding' job w/DNA-based liquid biopsy. But for RNA - RADAR is RNA and DNA… https://t.co/VfiQwMnjV6
3:17pm August 20th 2018 via Twitter Web Client
Jia #NGDx18 Have 5 tests: DDR (DNA damage repair 15 genes), LITE (pan cancer 81 genes), RNA fusions, two others.
3:12pm August 20th 2018 via Twitter Web Client
Jia #NGDx18 Founded '15, CLIA/CAP, clobalpresence, GeneRADAR liquid biopsy tech.
Shidong Jia (Predicine) Transforming immuno-oncology with ctRNA + ctDNA liquid biopsy solutions #NGDx18
3:11pm August 20th 2018 via Twitter Web Client
Bresler #NGDx18 Multiple solutions: change materials, change formulation w/stabilizers, or tightly control fluctuat… https://t.co/gJgnux5KdD
2:59pm August 20th 2018 via Twitter Web Client
Bresler #NGDx18 Found loss of reagent on side of vessel. Only when vessel was open, and temperature fluctuation on-instrument.
2:58pm August 20th 2018 via Twitter Web Client
Bresler #NGDx18 'Dealing with foreseeable misuse.' Want multi-organism panels, smartphone capable, and simple.
2:57pm August 20th 2018 via Twitter Web Client
Bresler #NGDx18 Don't forget about the science in the IVD: one of their customers had a reagent stable at 4C for 2y… https://t.co/FXCWbSFlY6
2:57pm August 20th 2018 via Hootsuite Inc.
Bresler #NGDx18 Technicians like lots of tape; their RF sensors won't work with tons of tape. So they invented a di… https://t.co/zWVG71lPPA
2:54pm August 20th 2018 via Twitter Web Client
Bresler #NGDx18 New tech: RF transmitters / receivers to sense sub-cutaneous fat vs injected fluid, and tunable.
2:53pm August 20th 2018 via Twitter Web Client
Bresler #NGDx18 CT scans may have contrast media injections. Want to prevent extravasation - contrast agent leaking into tissue.
2:52pm August 20th 2018 via Twitter Web Client
Bresler #NGDx18 Put a Sharpie 'dot' for the abnormal sites for prior workflow - so they designed a Sharpie to fit the instrument (!)
2:50pm August 20th 2018 via Twitter Web Client
Bresler #NGDx18 Example: Cytyc ThinPrep kits for getting a uniform layer of cells for Pap smears w/an imager. Walks… https://t.co/fosgfKDCJY
Bresler #NGDx18 For medical devices, it's different. Considering 'the chain of value propositions'; what are needs of all stakeholders?
2:47pm August 20th 2018 via Twitter Web Client
Bresler #NGDx18 An integrated dev process for human centric design: user research, concept dev, concept execution, testing/eval.
2:45pm August 20th 2018 via Twitter Web Client
Herbert Bresler (Battelle) NGDx18 Human centric design considerations for developing POC diagnostics
2:44pm August 20th 2018 via Twitter Web Client
Berger #NGDx18 Have established a clonal hematopoiesis clinic to help these pts. Future prospects: liquid biopsy, more comprehensive RNA/DNA
2:36pm August 20th 2018 via Twitter Web Client
Berger #NGDx18 They sequence not only tumor but matched normals; can look at ca predisposition. Can look at clonal… https://t.co/NmazI1BDL8
2:35pm August 20th 2018 via Twitter Web Client
Berger #NGDx18 Re-diagnosis of br cancer 5y later, metastatic spread to lymph. Found: 96% probability of lung cance… https://t.co/t3tyArYQZo
2:33pm August 20th 2018 via Twitter Web Client
Berger #NGDx18 Inferring tissue of origin: a machine-learning classifier. When they aggregate features (hotspots, f… https://t.co/PNR13Fh3zJ
2:31pm August 20th 2018 via Twitter Web Client
Berger #NGDx18 Found Whole Genome Doubling - about 30% of cases, assoc'd with poor prognosis. '18 https://t.co/n4IFXTkOCa
2:30pm August 20th 2018 via Twitter Web Client
Berger #NGDx18 MMR approved May '17; MSI-H or MMR-d solid tumors approved for PD-1 blockade. Their study on MSI: detected.
2:29pm August 20th 2018 via Twitter Web Client
